[DISCLOSURE] Komipharm International (041960) announced on Oct. 12 that its subsidiary in Australia has decided on a capital increase worth 18.9 billion won (US$16.82 million) through third-party allotment to finance its operations (2.06 billion won) and invest in facilities (16.89 billion won). 

A total of 149,612 shares will be issued to Korea Insight Investment and 33 others. The issue price is 126,729 won per share.

By Yun Jeong-hyeon (clareyun@heraldcorp.com)